Biotech Values

[randychub]

RVNC - Ticker Report - Any opinions on this source?

https://www.tickerreport.com/banking-finance/2574057/revance-therapeutics-inc-rvnc-receives-35-00-average-target-price-from-brokerages.html

Shares of Revance Therapeutics Inc (NASDAQ:RVNC) have been given an average recommendation of “Buy” by the six analysts that are covering the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $37.00.

RVNC has been the topic of several research analyst reports. Zacks Investment Research cut shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 9th. Aegis restated a “buy” rating and issued a $28.00 price objective on shares of Revance Therapeutics in a research report on Tuesday, February 28th.

Hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. raised its stake in shares of Revance Therapeutics by 0.9% in the first quarter. JPMorgan Chase & Co. now owns 3,459,844 shares of the biopharmaceutical company’s stock valued at $71,965,000 after buying an additional 29,686 shares in the last quarter. Franklin Resources Inc. raised its stake in shares of Revance Therapeutics by 5.6% in the fourth quarter. Franklin Resources Inc. now owns 3,280,584 shares of the biopharmaceutical company’s stock valued at $67,908,000 after buying an additional 173,305 shares in the last quarter. Arrowpoint Asset Management LLC raised its stake in shares of Revance Therapeutics by 10.7% in the fourth quarter. Arrowpoint Asset Management LLC now owns 2,018,729 shares of the biopharmaceutical company’s stock valued at $41,788,000 after buying an additional 195,515 shares in the last quarter. Polar Capital LLP raised its stake in shares of Revance Therapeutics by 13.0% in the third quarter. Polar Capital LLP now owns 1,319,871 shares of the biopharmaceutical company’s stock valued at $21,392,000 after buying an additional 151,329 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Revance Therapeutics by 5.1% in the first quarter. Vanguard Group Inc. now owns 868,118 shares of the biopharmaceutical company’s stock valued at $18,056,000 after buying an additional 42,466 shares in the last quarter.